answers, page-26

Zab,

$50m of revenue means about $30m NPAT which is what a company can pay dividends out of and usually the "E" in a PE multiple. At anything about above 10c we will have 800m on isse (options excercise) so 50-60c is about 15x and a fair multiple to use for what would be a huge growth trajectory.

As usual we are waaaaay ahead of ourselves.

It sounds like we are locked into cash flow positive status by the confidence of the responses in the update but that won't be proven till Q2 next year unless a big signature arrives before then.

Until then we are just a small biotech spec with a lot of potential. I think a fair value for what we know already is 10-20c but this is a tough market so it is what it is.